12 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
15771450	42	Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesity.	Laboratorios Dr. Esteve
21924902	43	5-(2'-Pyridyl)-2-aminothiazoles: alkyl amino sulfonamides and sulfamides as potent NPY(5) antagonists.	Lundbeck Research Usa
21782428	61	Discovery of Lu AA33810: a highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder.	Lundbeck Research Usa
19720539	32	Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist.	Tsukuba Research Institute
19464889	43	Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.	Tsukuba Research Institute
15109631	86	Discovery and SAR of potent, orally available and brain-penetrable 5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen- and 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulen derivatives as neuropeptide Y Y5 receptor antagonists.	Novartis Pharma
12593645	2	In vitro and in vivo characterization of 3-[2-[6-(2-tert-butoxyethoxy)pyridin-3-yl]-1H-imidazol-4-yl]benzonitrile hydrochloride salt, a potent and selective NPY5 receptor antagonist.	Pfizer
12139462	34	Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity.	Astrazeneca
12067557	24	Discovery of potent and selective small molecule NPY Y5 receptor antagonists.	Lundbeck Research Usa
10866375	50	Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists.	Novartis Pharma
9925722	18	Pharmacological treatment of obesity: therapeutic strategies.	The R. W. Johnson Pharmaceutical Research Institute